Saturday, May 14, 2011

fingolimod (therapeutic use) -- MeSH and keywords

"fingolimod" [Supplementary Concept] AND ("Propylene Glycols/therapeutic use"[Mesh] OR "Sphingosine/therapeutic use"[Mesh])

( Fingolimod* OR Fingolimod OR Fingolimodum OR FTY-720 OR "FTY 720" OR FTY720 OR Gilenya)

azilsartan medoxomil (therapeutic use) -- MeSH and keywords

"azilsartan medoxomil" [Supplementary Concept] AND ("Benzimidazoles/therapeutic use"[Mesh] OR "Oxadiazoles/therapeutic use"[Mesh])

(Azilsartan* OR Azilsartan OR Azilsartanum OR TAK-491 OR "TAK-491" OR TAK491 OR edarbi)

alglucosidase alfa (therapeutic use) - MeSH and keywords

"GAA protein, human" [Supplementary Concept] AND "alpha-Glucosidases/therapeutic use"[Mesh]


(Alglucosidase OR Alglucosidasa OR Alglucosidasum OR rhGAA OR Lumizyme OR Myozyme OR alpha-glucosidase OR "acid maltase" OR LYAG)

Pegloticase (therapeutic use) -- MeSH and keywords

"polyethylene glycol-uricase" [Supplementary Concept] AND ("Polyethylene Glycols/therapeutic use"[Mesh] OR "Urate Oxidase/therapeutic use"[Mesh])


(pegloticas* OR Pegloticase OR Pegloticasa OR Pegloticasum OR Krystexxa OR "glycol uricase" OR "glycol-uricase" OR puricase OR "glycol-conjugated uricase")

Lisdexamfetamine

"lisdexamfetamine dimesylate" [Supplementary Concept] AND "Dextroamphetamine/therapeutic use"[Mesh]


(Lisdexamfetamin* OR Lisdexamfetamine OR Lisdexamfetamini OR lisdexanfetamina OR NRP-104 OR "NRP 104" OR NRP104 OR Vyvanse)

tesamorelin (therapeutic use) -- MeSH and keywords

"tesamorelin" [Supplementary Concept] AND "Growth Hormone-Releasing Hormone/therapeutic use"[Mesh]

(Tesamorelin* OR tesamorelina OR Tésamoréline OR Tesamorelini OR TH-9507 OR "TH 9507" OR TH9507 OR TH-9507 OR Egrifta )

duloxetine (therapeutic use) -- MeSH and keywords

(("duloxetine" [Supplementary Concept]) AND "Thiophenes/therapeutic use"[Mesh])

(Duloxetine OR duloxetin* OR Duloxetina OR Duloxetini OR duloxetina OR LY-248686 OR "LY 248686" OR LY248686 OR Ariclaim OR Cymbalta OR Delok OR Duceten OR Duxetin OR Xeristar OR Yentreve)